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Poster Session II S317the results obtained there correlated with our findings. All samples
containing Hb Barts were confirmed as a+-Thalassemia minima,
which is a clinically not relevant outcome. The hemoglobin variant
detected in the Hb E-zone turned out to be the heterozygous, and
therefore clinically not relevant, Hb F-Campinas.
Discussion:Hemoglobin electrophoresis using the Capillarys 2 sys-
tem by Sebia proved to be an efficientmethod to screen for hemoglo-
binopathies in cord blood. So far, the ratio of detected
hemoglobinopathies is lower than what previously published studies
suggested. It has to be taken into account that this is not an epidemi-
ological study, but instead relies on a restricted group of patients -
namely newborns that donated Cord Blood.451
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Toxicities and complications associated with hematopoietic cell
transplantation (HCT) currently limit this potentially curative ther-
apy for malignant and non-malignant blood disorders in the clinic.
Similar to outcomes in patients, miniature swine develop severe
GVHD, infectious complications or hematopioetic failure following
standard clinical myeloablative conditioning and HCT. Miniature
swine recipients pre-treated with a low-dose (100cGy) of total
body irradiation (TBI), partial T-cell depletion using a CD3-immu-
notoxin prior to HCT and a 45 day course of Cyclosporine A
(referred to as ITC non myeloablative conditioning) following
high-dose haploidentical-HCT (5-15X109 PBMCs/kg) exhibit sta-
ble engraftment and multilineage chimerism. We have observed
a wide variability in engraftment outcomes depending on the occur-
rence of adverse reactions (fever, loss of appetite, bloody diarrhea,
shedding of the GI lining and development of disseminated intravas-
cular coagulopathy [DIC]) in the donor (‘‘DIC Donor’’) following
cytokine mobilization at the time of HC donation. ITC recipients
(n 5 12) that received haploidentical HCT from donors that re-
mained healthy (‘‘Healthy Donors’’) during IL-3 and stem cell factor
(SCF) mobilization, engrafted with multilineage chimerism, did not
develop GVHD and did not require any blood product support. In
contrast, ITC recipients (n 5 11) that received a stem cell product
from a DIC Donor mobilized with IL3 and SCF had adverse out-
comes. All recipients (11/11) lost peripheral blood myeloid chime-
rism (i.e. lack of donor stem cell engraftment). Also, all animals
that received an HCT graft from DIC Donors developed moder-
ate-severe thrombocytopenia (\ 100,000 PLT/uL) and 73% (8/
11) developed severe and life threatening thrombocytopenia (un-
der/equal 20,000 PLT/uL) which required blood product support.
One animal developed grade IV acute GVHD on day 30 post
HCT. In contrast only 2/12 (16%) of animals receiving a transplant
from Healthy Donors had thrombocytopenia with levels falling un-
der 100K, none required blood product support and none developed
GVHD. These data suggest that engraftment outcomes and post-
transplant complications are greatly influenced by the health status
of the donor prior to collection of cells by leukapheresis.We are cur-
rently investigating the causes of possible factors responsible for the
poor engraftment outcomes.
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Objective: to analysis the outcome of allogenic hematopoiteic stem
cell transplant (HSCT) for children with aplastic anemia (AA) in
China. To improve the evidence based HSCT indication for pediat-
ric AA.
Method:: retrospectively analysis pediatric AA receivedHSCT from
2002-2009 in Chinese Pediatric Group of HSCT.
Results: 64 patients from 8 hospitals enrolled in this group(16
VSAA, 44 SAA and 4 CAA). The median age was 7.5 years old (1-
16.5y). Because 5 of 11 received second HSCT totally 69 transplan-
tation were performed with 30 matched sibling donor, 24 matched
unrelated donor and another 15 haploidentical family donor. 53%
received CY120mg+ATG+Flu150-200mg+TBI3GY,38% received
CY120mg+ ATG+ Flu150-200mg and only 9% received CY120m-
g+ATG condition regimen. For the sources of hematopoietic stem
cell 45% with PB, 34% with PB+BM,17% with BM and only 4%
with CB. After median follow up 26 months (10-95 months) 11 of
64(15.9%) suffered graft failure (3 with secondary graft failure).ex-
cept 2 lost follow up post transplant 11 and 23 months, 7 patients
died of transplant related mortality (6 with infection and only one
with aGVHD) and another 55 (85.9%) got disease free survive.
There was significant difference of overall survival (OS) for patients
older or younger than 10 years(96% vs 71%, p5 0.037)and patients
with BMT than PBSCT or CBT(100% vs 85% and 67%, p5 0.05).
Although II-IV aGVHD was significant different between MSD,
MUD or haploidentical transplant (22.2%, 45% vs 66.6%, P 5
0.003)there was no any different of the OS among these three
groups(93%,85% vs 80%, P 5 0.526).
Conclusion: HSCT is an effective method to rescue children with
AA. Comparing with PB and CB, BM is much better for children
with AA. Although aGVHDwasmuch frequent inMUDand heploi-
dentical donor transplant, it can be controlled and without interfer-
ence with the OS. Because the outcome of MUD or haploidentical
donor transplantation is the same as MSD donor transplant, which
is much better than IST for pediatric AA in China. It is reasonable
to consider the high resolution well matched unrelated donor trans-
plant as the first line treatment for SAA children in our country.453
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Allo SCT is the treatment of choice for various pediatric malig-
nancies. A matched sibling donor (MSD) is always preferable but
only 25%of pts have such a donor. All other pts have to receive trans-
plants from unrelated donors (URD), either adult volunteers or cord
blood units. Transplant results with URD for children with hemato-
logic malignancies have improved due to the increase in the donor
pool and more experience of transplant centers (BMT
2004;34:901, Blood 2010; 116: 1839). We review our experience
with allo SCT for children with hematological malignancies com-
paring the results between MSD vs URD grafts.
Patients and Methods: 61 pediatric pts. received an allo SCT for
hematologic malignancy from 1989 through 2010 at a single institu-
tion. 40 received the graft from MSD and 21 from URD (18 pts 0-1
mismatch cord blood unit and 3 full matched adult donors). Both
groups were balanced for diagnosis (ALL 52% vs 52%, AML 32%
vs 33%, CML/MDS 15% vs 14%), disease stage (ALL and AML:
CR1 35% vs 33%, CR2 35% vs 38%, . CR2/refractory 14% vs
10%) and use of TBI in the conditioning regimen (78% vs 90%).
Overall survival, relapse and transplant related mortality (TRM,
any time after SCT) were analysed with the Kaplan Meier method
and compared with the LogRank test.
Results: with a median follow up time of 3 years overall survival is
46%; 45% for the MSD group and 48% for the URD. Relapse
was 50% for MSD vs 29% for URD (p 5 0,09) and MRT was
21% for MSD vs 32% for URD (p 5 0,33).
Conclusion: pediatric pts. with hematologic malignancies and a def-
inite indication for allo SCT should proceed to transplant as soon as
an adequate donor is found (MSD or URD).
